Email updates

Keep up to date with the latest news and content from Malaria Journal and BioMed Central.

Open Access Highly Accessed Commentary

Malaria prophylaxis policy for travellers from Europe to the Indian Sub Continent

RH Behrens1*, Z Bisoffi2, A Björkman3, J Gascon4, C Hatz5, T Jelinek7, F Legros6, N Mühlberger7, TropNetEurop and P Voltersvik8

Author Affiliations

1 Hospital for Tropical Diseases & London School of Hygiene & Tropical Medicine, London, UK

2 Centro per le Malattie Tropicali, Ospedale S. Cuore, Negrar Verona, Italy

3 Department of Medicine, Unit of Infectious Diseases, Karolinska Institute, Stockholm, Sweden

4 Centre de Salut Internacional, Hospital Clinic, IDIBAPS, Barcelona, Spain

5 Swiss Tropical Institute, Basel, Switzerland

6 Centre National de Référence pour le Paludisme d'Importation et Autochtone, France

7 Institute of Tropical Medicine, Berlin, Germany

8 The Gade Institute, Haukeland University Hospital, Bergen, Norway

For all author emails, please log on.

Malaria Journal 2006, 5:7  doi:10.1186/1475-2875-5-7

Published: 1 February 2006


Analysis of malaria imported into eight European countries from the Indian sub-continent (ISC) (India, Pakistan, Bangladesh and Sri Lanka) led to a consensus statement on the use of chemoprophylaxis within TropNetEurop. The proportion of cases from the ISC in 2004 ranged from 1.4%–4.6% of total imported cases. Plasmodium falciparum cases reported from the eight countries was only 23 (13% of all cases from the region). Total malaria reports between 1999–2004 fell from 317 to 180. The risk of malaria in UK residents visiting the region was > 1 case per 1,000 years exposed. The group recommended non-selective prescribing of chemoprophylaxis for visitors to India, Pakistan, Bangladesh and Sri Lanka should be dropped.